This company has been marked as potentially delisted and may not be actively trading. Talaris Therapeutics (TALS) News Today Add Compare Share Share Headlines Stock AnalysisCompetitorsDividendInsider TradesTrendsBuy This Stock TALS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Tourmaline Bio, Inc. (TRML)August 21, 2024 | finance.yahoo.comCullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial OfficerApril 29, 2024 | finanznachrichten.deLongitude Venture Partners III, L.P.'s Net WorthFebruary 25, 2024 | benzinga.comRA Capital Management L.P. Takes Position in Talaris Therapeutics, Inc. (NASDAQ:TALS)December 12, 2023 | marketbeat.comTalaris Therapeutics (TALS) Price Target Increased by 562.50% to 135.15November 1, 2023 | msn.comTalaris Therapeutics goes ex-dividend tomorrowOctober 19, 2023 | msn.comTalaris Therapeutics, Inc.: Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline BioOctober 18, 2023 | finanznachrichten.deTalaris shareholders approve merger, 1-for-10 reverse stock splitOctober 17, 2023 | msn.comTalaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline BioOctober 17, 2023 | finance.yahoo.comShares of Talaris Therapeutics Climb 5.2% on Special Dividend Tied to MergerOctober 6, 2023 | marketwatch.comTalaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline BioOctober 6, 2023 | finance.yahoo.comNew York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris TherapeuticsOctober 4, 2023 | finance.yahoo.comWe're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn RateSeptember 12, 2023 | finance.yahoo.comAcadian Asset Management LLC Raises Holdings in Talaris Therapeutics, Inc. (NASDAQ:TALS)September 7, 2023 | marketbeat.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, DEN, TALS, QUOTAugust 15, 2023 | markets.businessinsider.comImmunoFree Inc. has Acquired Talaris Therapeutics, Inc.'s Tolerance BusinessAugust 14, 2023 | finance.yahoo.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, TALS, QUOT, SURFAugust 8, 2023 | markets.businessinsider.comMoore Kuehn Encourages RETA, TALS, INPX, and DEN Investors to Contact Law FirmJuly 28, 2023 | benzinga.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Talaris Therapeutics, Inc. (TALS)July 27, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NETI, QUOT, TALS, CFMSJuly 18, 2023 | markets.businessinsider.comTalaris Therapeutics: Cashing Out Ahead Of Tourmaline MergerJuly 18, 2023 | msn.comShort Interest in Talaris Therapeutics, Inc. (NASDAQ:TALS) Decreases By 71.7%July 14, 2023 | marketbeat.comTalaris Therapeutics (TALS) Price Target Increased by 66.67% to 12.75July 6, 2023 | msn.comIMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, DICE, NEX, NETIJune 27, 2023 | markets.businessinsider.comTALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALSJune 26, 2023 | businesswire.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Talaris Therapeutics, Inc. MergerJune 23, 2023 | benzinga.comTalaris Therapeutics announces merger after layoffsJune 23, 2023 | bizjournals.comNY biotech to go public by merging with Boston firm that laid off 95% of staffJune 22, 2023 | bizjournals.comTalaris jumps 29% on merger with Tourmaline Bio in all-stock dealJune 22, 2023 | msn.comIMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, SURF, NEX, CIRJune 22, 2023 | markets.businessinsider.comTalaris Therapeutics, Inc.: Talaris Therapeutics and Tourmaline Bio Announce Merger AgreementJune 22, 2023 | finanznachrichten.deTalaris Soars on All Stock Deal with Tourmaline BioJune 22, 2023 | msn.comTALS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Talaris Therapeutics, Inc. Is Fair to ShareholdersJune 22, 2023 | stockhouse.comWhy Talaris Therapeutics Stock Is Shooting Higher TodayJune 22, 2023 | benzinga.comTalaris to merge with Tourmaline Bio in all-stock dealJune 22, 2023 | seekingalpha.comTourmaline, Talaris Announce All-stock MergerJune 22, 2023 | markets.businessinsider.comTalaris Therapeutics and Tourmaline Bio Announce Merger AgreementJune 22, 2023 | finance.yahoo.comTalaris Therapeutics (Nasdaq:TALS) HeadlineTrading was temporarily halted for "TALS" at 07:06 AM with a stated reason of "News pending."...June 22, 2023 | marketbeat.comTalaris Therapeutics Board Member Awarded $50K Worth of Stock OptionsJune 15, 2023 | benzinga.comTalaris Therapeutics Director Awarded $50K Worth of Stock OptionsJune 15, 2023 | benzinga.comTalaris Therapeutics, Inc. (NASDAQ:TALS) Director Sells $62,530.74 in StockJune 9, 2023 | marketbeat.comTalaris Therapeutics, Inc.: Talaris Therapeutics Announces Leadership TransitionMay 26, 2023 | finanznachrichten.deTalaris Therapeutics Names Mary Kay Fenton Interim CEO & President - Quick FactsMay 26, 2023 | markets.businessinsider.comTalaris Therapeutics appoints current CFO Mary Kay as interim CEOMay 26, 2023 | msn.comTalaris Therapeutics Announces Leadership TransitionMay 26, 2023 | finance.yahoo.comTalaris Therapeutics, Inc. (NASDAQ:TALS) most popular amongst private equity firms who own 34% of the shares, institutions hold 30%May 20, 2023 | finance.yahoo.comQ2 2023 EPS Estimates for Talaris Therapeutics, Inc. (NASDAQ:TALS) Increased by SVB LeerinkMay 19, 2023 | marketbeat.comWellesley biotech announces 2nd round of layoffs this year, closure of Kentucky facilitiesMay 3, 2023 | bizjournals.comTalaris Therapeutics closing Louisville facilities, laying off 51May 2, 2023 | bizjournals.comTalaris Therapeutics Stock (NASDAQ:TALS), DividendsApril 18, 2023 | benzinga.com Get Talaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TALS and its competitors with MarketBeat's FREE daily newsletter. Email Address TALS Media Mentions By Week TALS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TALS News Sentiment▼0.000.96▲Average Medical News Sentiment TALS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TALS Articles This Week▼00▲TALS Articles Average Week Get Talaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TALS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Prime Medicine News Inhibikase Therapeutics News Protalix BioTherapeutics News Invizyne Technologies News ZIVO Bioscience News Calidi Biotherapeutics News AlloVir News NKGen Biotech News CEL-SCI News Chromocell Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TALS) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
